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Abstract  Psychosomatic  disorders  are  among  the  most  common  psychiatric  disorders  in  gen-
eral practice,  with  a  prevalence  of  16%.  These  patients  often  turn  to  different  general
practitioners  and/or  non-psychiatric  specialists  for  long  periods  of  time  and  represent  a  diag-
nostic and  therapeutic  challenge,  as  the  possible  organic  component  makes  it  complex  and
difficult to  manage.
The  reported  case  is a  24-year-old  male  patient  with  a  diagnosis  of  Somatic  Symptoms  Disorder
and multiple  psychiatric  comorbidities.  The  purpose  of  this  study  is  to  review  the  reconceptu-
alization  of Somatoform  Disorders’  DSM-5  diagnosis,  which  can  be  useful  for  psychiatrists  and
non-psychiatric  physicians  for  the  approach  and  management  of  these  patients.
© 2014  Universidad  Autónoma  de  Nuevo  León.  Published  by  Masson  Doyma  México  S.A.  All  rights
reserved.
Introduction
Psychosomatic  disorders  are  among  the  most common  psy-
chiatric  disorders  in  general  practice,  with  a  prevalence
of  16%.1--3,5 Before  going  to  a  psychiatrist,  these  patients
usually  see  general  physicians  and/or  non-psychiatric  spe-
cialists  for  long  periods  of  time2,4,6 which  is  enabled  by  these
patients’  resistance  to  acknowledging  that  their  physical
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problem  can  be  linked  to  or  exacerbated  by  an emotional
and  not only  an organic  origin,  resulting  in multiple  thera-
peutic  managements  and  chronic  use  of  health  services.2,4,5,8
Moreover,  the  important  association  of psychiatric
comorbidity  (depression,  anxiety  and psychopathology  of
character),  as  well  as  medical  illnesses,1,2,4,6,7 makes  them  a
diagnostic  and treatment  challenge  not  only  for  the  psychia-
trist,  but  also  for  general  practitioners  and  other  specialties,
since  the possible  organic  component  makes  them  complex
and  difficult  to  manage.4,7
Regarding  its  evolution,  chronicity,  social  and interper-
sonal  dysfunction,  difficulties  at work  and  the frequent
use  of medical  services  are  the  common  characteristics
of  these disorders,  which  lead  to  an elevated  level  of
dissatisfaction  in both  the doctor  and  the patient.5,7,8
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The  present  article  presents  the  case  of  a  patient  who  exem-
plifies  this  pathology.
Case presentation and  discussion
The  patient  is  a  24-year-old  male,  from Monterrey,  Mexico.
He  is single,  works  at  a flea  market,  with  an upper  secondary
level  of  completed  education  and  a  low  socioeconomic  sta-
tus.  He  had  a  background  of  excellent  school  performance
with  academic  scholarship  through  secondary  school  and
high  school.  Prior  to  the onset  of the psychopathology,  there
was  adequate  and  constant  work  activity,  as  well  as  more
social,  recreational  and  interpersonal  involvement.  During
his  childhood,  he  refers  to  being sexually  abused  (improper
touching)  on  two  occasions  and  describes  a  stressing  family
environment  with  constant  verbal  and  psychological  abuse
toward  him  and  other  family  members.  This  prolongs  until
adolescence.  Subsequent  to  his  parents’  separation,  he
maintains  a  scarce,  almost  null,  relationship  with  his  father,
which  stands  as  an event  which  impacts  his  childhood  and
personal  development  in a negative  way.
He  has  attended  the Psychiatric  Outpatient  Clinic  volun-
tarily  on  July  2012  after  presenting  depressive  symptoms
for  more  than  6 months,  secondary  to  pollakiuria  with
an  evolution  of  4 years,  which  began  after  his  father’s
death,  presenting  20--25  urinations  a  day,  with  intervals
of  10--20  min in-between  and without  disrupting  sleeping
hours.  He  denies  pain  while  urinating,  pushing,  tenesmus,
fever  or  any  other  added  symptoms.  Over  4 years  the
patient  saw  multiple  doctors  and  different  urologists,  who
requested  para-clinical  studies,  with  different  non-certain
diagnoses  and diverse  pharmacological  treatments  without
improvements  in the urinary  symptom.  (Table  1)
At  first,  in view  of  the diagnostic  doubt  and  lack  of
response  to  treatments,  the patient  thought  that  the  ori-
gin  of the symptom  was  caused  by  a physical  illness;  then,
he  associated  it with  the  unresolved  mourning  of  his  father’s
death  which concurs  with  the onset  of  the symptoms.
Secondary  to the onset  of  the urinary  symptom,  the
patient  interrupts  his personal  and professional  growth:
quits  his  job,  stops  frequenting  his  friends  and  remains  iso-
lated  at home  for  over  2 years,  focusing  his  life  on  attending
specialists  and  trying  to  solve  his  symptoms.  Two  years  later,
the patient  reduces  the  frequency  of urination,  accomplish-
ing  a urination  rate  of  once  every  2  h,  and  begins  working
part-time.  However,  the  sense  of  urgency  to urinate  as  well
as  the constant  preoccupation  of not being  able  to  reach  a
place  to  urinate,  lead  to  a poor  working  growth  and avoid-
ance  of  interpersonal  relationships  with  limited  social  and
recreational  activities.
Table  1  Medical  history  in relation  to  the  urinary  symptom.
Date  Diagnostic  studies  Diagnosis  Treatment
March  2009  EGO  -- normal
Pelvis  and  kidney  Eco  -- normal
Not  specified  Not  specified
March 2009  Prostatic  Ag. --  normal
EGO  -- normal
Urine  culture  -- Enterococcus  Sp.
Urinary  tract  infection  Lincomycin  IM  Erythromycin
VO
May 2009  Spermculture:  Klebsiella  Sp.  Prostatitis  Erythromycin
June 2009  Spermculture  --  S.  aureus
Klebsiella
Prostatitis  TMP/SMZ
July 2009 Retrograde  urethrography:  narrowness  of  the
prostatic  urethra.  Checked  with  US  finding  the
prostate  to  have  normal  dimensions  and
caliber.  Complete  emptying  of  urine.
Prostatitis  Alfuzosin
December 2009  Spermculture  --  S.  aureus  Prostatitis  TMP/SMZ
January 2010  Spermculture  --  S.  aureus  +  Proteus  vulgaris
Urine  culture  -- negative
EGO  -- normal
Prostatitis  TMP/SMZ
Meloxicam
Terazosin
February 2010  No  studies  prescribed  (review  of  previous).  Not  specified  Alfuzosin
Espectinomicina
Azithromycin  Finasteride
Pregabalin
June 2010  No  studies  prescribed.  Overactive  bladder
syndrome
Solifenacin
Fluoxetine
November 2010  Excretory  urography:  normal  Likely  left  ureterocele  Recommends  surgery
December 2010  Urodynamic  study  prescribed:  not  performed
due to  lack  of  economic  resources.
Not  specified  Diazepam
January 2011  Refer  nondiagnostic  ureterocele  Prostatitis  Solifenacin
May 2012  Urine  smear  --  negative
Urine  culture  -- Enterobacter  cloacae
EGO - normal
Prostatic  US  --  normal
Not  specified  Levofloxacin
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Six  months  prior  to  attending  psychiatric  consultation
he  begins  to  feel  sadness  every  day  for  almost  the entire
day;  this  sadness  is  linked  to  his  urinary  problem  and  his
difficulties  in accomplishing  things  in  his  personal  life  and
at  work.  He  refers  to  feeling  ‘‘handicapped’’,  saying  he
felt  ‘‘like  trash’’,  occasional  crying,  anhedonia  and melan-
choly.  A  month  ago  he  began  to  present  terminal  insomnia,
reduction  of  appetite,  weakness  and  occasional  feelings  of
hopelessness,  causing  significant  discomfort  which  inter-
feres  with  his  performance  in his  everyday  activities.  He
denies  having thoughts  of  death,  or  suicidal  thinking  and/or
planning.
Previous  to  the pollakiuria,  a pattern  of  preoccupation
about  trivial  situations  with  a  tendency  for  the catastrophic
is  noticed,  which  causes  a persistent  and general  anxiety
not  limited  to a specific  situation  and  is  manifested  by  con-
stant  hand  sweating,  palpitations,  mild  tremors,  occasional
irritability,  fatigue  and  difficulty  focusing.  The  anxiety  symp-
toms  fluctuate,  but  have  a long  evolution,  which  has  been
exacerbated  over  the  last  6  months.
Structural exam
The  patient  manifests  evasive  and dependent  behavior,
which  has  had  him  working  for  the  last  2 years  at a  place
which  does not  represent  a  significant  challenge  nor  does  it
demand  formal  obligations,  hiding  behind  his  urinary  prob-
lem  to  avoid  looking  for  a  stable  job,  with  a  dependent
and  victimized  line.  The  evasive  behavior  is  also  manifested
by  his  disproportional  fear  when  facing  everyday  situations,
generating  anguish  and resulting  in deterioration  of  work
and  interpersonal  relations.
He  presents  a  predominately  devaluated  self-concept,
describing  himself  as  scared,  insecure  and  feeling  that  he
has  little  value;  this  interferes  with  his  interpersonal  rela-
tionships  with  others.  He  displayed  defense  mechanisms,
mainly  repressive,  like rationalization,  constantly  using  his
urinary  symptom  as  an  excuse  to  justify  his  evasive  and
dependent  traits;  affective  isolation  when describing  his
father’s  death as  an event  that  caused  little  pain  and dis-
placing,  redirecting  that  pain  toward  his  urinary  symptom.
Despite  his  difficulty  to  relate  to  others,  he  manifests
an  ability  to  empathize  with  others  and  an ability  to  be
grateful,  expressing  gratitude  for  the time  dedicated  to his
evaluation.  Regarding  his  aggressive  impulses’  control,  he
does  not  present  frequent  situations  which  put  him  in con-
flict,  thus  making  his  ability  to contain  and  repress  emotions
evident.  However,  on a few  occasions  we  were  able  to  see
the  infiltration  of  primary  process  thinking,  causing  him  to
make  impulsive  decisions,  later  realizing  this  through  his
ability  for  self-reflexive  thinking.
In  respect  to  the  quality  of  his  interpersonal  relation-
ships,  he  is  unable  to  establish  long  lasting  friendships
or  romantic  relationships  and  maintains  a superficial  and
not  very  affective  relationship  with  his  family  members.
Regarding  his  tolerance  of  anxiety,  we  can observe  a  peren-
nially  apprehensive  tendency  and  a  tendency  to  exaggerate
catastrophes,  which is  expressed  through  his  urinary  fre-
quency  and  in everyday  situations,  like  sweaty  palms when
interacting  with  people,  and  in his  sex  life,  presenting  antic-
ipatory  anxiety  of  not  reaching  a  full erection.
Despite  observing  in the  patient  the  cognitive  ability  and
desire  to  develop  the personal  and professional  aspects  of
his  life,  he does  not  perform  any  type  of  activities  where  he
experiences  pleasure  and  satisfaction.
The  patient  has  self-reflexive  ability  to  suggest  that  pol-
lakiuria  is  the superficial  symptom  covering  deeper  problems
related  to self-esteem  and  his  character.
DSM-V diagnosis
300.82.  Somatic  Symptom  Disorder.
300.02.  Generalized  Anxiety  Disorder.
296.21  Major  Depressive  Disorder.
3001.9  Unspecified  Personality  Disorder.
Diagnostic analysis
The  DSM-V  modifies  the Somatomorphic  Disorders  and  cre-
ates  a  new  diagnostic  entity  in its  place;  Somatic  Symptoms
Disorder  (SSD)  and  related  disorders.  Evidence  of  multiple
lab  and imaging  studies  without  significant  pathological  find-
ings,  which  explain  the  severity  of  the  symptoms,  along  with
the  lack  of response  to  several  medical  treatments  given
by  different  urologists,  ruled  out  the presence  of  a known
medical  condition  that  could  explain  the patient’s  urinary
symptom,  thus  concluding,  according  to  the DSM-V,  the pres-
ence  of  a  SDD  (Table 2).8
The  urinary  symptom  generated  discomfort  and major
anxiety  which  impacted  the different  areas  of  the patient’s
life  in  a  negative  way,  since  the constant  feeling  of  inability
hindered  his development  in his  work,  social  and personal
life  (Criterion  A).  The  symptom  became  the center  of  his
life,  and  he devoted  excessive  time  and  energy  worrying
about  his  health  and  searching  for  an effective  treatment
for  over  4 years  (Criteria  B and  C).  The  sudden  onset,  with  a
persistent  course  and long  evolution  of  a  single  very  severe
somatic  symptom,  producing  marked  anxiety  and disability
in  his  everyday  life,  specifies  the diagnosis  as  Severe  Persis-
tent  Somatic  Symptoms  Disorder.
The  new  components  of  somatic  symptoms  disorders  are
incorporated  in this  new  edition  of  the  DSM-V:  affection,
cognition  and behavior  within  SSD  criteria,  providing  a more
accurate  and  more  comprehensive  vision  of  the patients’
real  signs and  symptoms,  in comparison  to  the DSM-IV,  which
evaluates  only somatic  symptoms  (1 or  more). This  diagnos-
tic  reconceptualization  provides  a  useful tool  for  primary
care  doctors  or  any other  non-psychiatrist  specialist.  This
could  be very  beneficial  in  order  to  reach  a  proper diagnosis
and  treatment  in an earlier  manner,  improving  the prognosis
and  avoiding  economic  expenses  in healthcare.6,7,9,10
Additionally,  the criteria  for a  major  depressive  disorder,
with  a  moderate  single  episode,  are met,  clinically  evident
and  verbally  expressed  by  the  patient.
Regarding  anxiety  symptoms,  these were  reported  before
the  onset  of  the urinary  symptom,  with  exacerbation  in
the last  6 months,  causing  significant  discomfort.  The  non-
specified  personality  disorder  is justified  by  presenting
evasive  traits  manifested  in social  inhibition,  feelings
of  inability,  hypersensitivity  to  negative  evaluation  and
avoidance  of  activities  which  require  significant  interper-
sonal  contact,  causing  clinically  significant  dysfunction  and
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Table  2  Diagnostic  criteria  for  Somatic  Symptoms  Disorder  DSM-V.
Somatic  Symptoms  Disorder
A.  One  or  more  somatic  symptoms  that  cause  discomfort  or lead  to  significant  problems  in  everyday  life.
B. Excessive  thoughts,  feelings,  or behaviors  related  to  the  somatic  symptoms  or  associated  with  preoccupation  over
health as  is manifested  by  one  or  more  of  the  following  characteristics:
1. Disproportionate  and  persistent  thoughts  about  the  severity  of  the patient’s  own  symptoms.
2. Persistently  elevated  degree  of  anxiety  about  the  patient’s  health  or  symptoms.
3. Excessive  time  and  energy  dedicated  to  these  symptoms  or  to  worrying  about  health.
Although a somatic  symptom  may  not  be  continually  present,  the  symptomatic  disorder  is persistent  (generally  more  than
six months).
Specify  if:
Predominance  of pain  (before  painful  condition):  this  specifier  applies  to  individuals  whose  somatic  symptoms  imply
pain over  all.
Specify  if:
Persistent:  A  persistent  course  is characterized  by  the  presence  of  intense  symptoms,  important  alteration  and
prolonged  duration  (more  than  six  months).
Specify  the  actual  severity:
Light:  Only  matches  one  of  the  symptoms  specified  in  criterion  B.
Moderate:  Matches  2  or  more  of  the  symptoms  specified  in  criterion  B.
Severe: Matches  2 or  more  of the  symptoms  specified  n  criterion  B and  additionally  multiple  somatic  complaints  exist
(or one  very  intense  somatic  symptom).
discomfort  in social,  work  and  interpersonal  areas.  We  can
also  observe  dependent  personality  traits  with  the patient’s
difficulty  to  make  decisions  and not  assuming  responsibility
according  to  his  age  and stage in life.
Therapeutic plan
When  SSDs  coexist  with  a mood  or  anxiety  disorder,  the
administration  of  psychiatric  medications  is  indicated,  along
with  a  psychotherapeutic  treatment.  Therefore,  we  decided
to  follow  a  combined  treatment.2,5,12--14
Pharmacological treatment
The pharmacological  treatment  approach  to  SSDs  has been
complicated  due  to  the lack  of  conceptual  clarity  and  exces-
sive  emphasis  on  the psychosocial  causation  and  efficacy
of  psychological  treatments.15 Every  type  of  psychiatric
medication  is  used in clinical  practice  to  treat  SSDs, and
there  are  systemic  studies  focused  on  five  main  medication
groups:  tricyclic  antidepressants  (TCAs),  inhibitors  of  sero-
tonin  reuptake  (SRI),  serotonin  and noradrenaline  reuptake
inhibitors  (SNRIs),  atypical  antipsychotics,  and herbal-based
medications.12,15 Evidence  shows  that these five  groups  are
effective  for  a  wide  variety  of  disorders  and  that  all  types
of  antidepressants  seem  to  have  certain degree  of effective-
ness  on  SDDs  and related  disorders.12,13,15 TCAs  and  SRIs  are
the  most  utilized  pharmacological  agents  in SSDs.  Neverthe-
less,  there  are  little  data  supporting  its  effectiveness  as  a
stand-alone  treatment.2,5,12,13
The  research  leaves  many  unanswered  questions  about
dosage,  treatment  duration,  improvement  sustainability  in
the  long  run  and  variability  in  responses  to  different  types
of  medications.15 According  to  Carlat  (2012)  the  evidence  of
somatic  treatment  of  depression  in adults  reports  sertraline
to  be  a  first-choice  antidepressant  that  is  hard to  top,  given
its  combination  of efficacy,  tolerability  and  low cost.16
In the reported  case,  50  mg  of  sertraline/day  is  pre-
scribed,  along with  long-acting  benzodiazepine  (clonazepam
0.5  mg)  at  night  due to  the  presence  of comorbidity
with  depression  and  anxiety.  The  depression  symptoms  are
resolved  within  2 months;  however,  doctors  decided  to  dou-
ble the  sertraline  dosage  (100  mg)  at 6 weeks  and  triple it
(150  mg)  at 3 months  due  to the  persistence  of  the anxiety
symptom.  The  urinary  symptom  occurs  with  less  frequency
until  it  is  fully  resolved  after 6  months  of  combined  treat-
ment.  Clonazepam  is suspended  after 4  months  due  to  a good
response to  the antidepressant  and to  avoid  dependence  on
the  medication.  Because  of the significant  improvement  in
the  urinary  symptom  as  well  as  the depressive  and  anxiety
symptoms,  SRI  is  gradually  reduced  to  50  mg/day  until  its
full  suspension  2 years  later.  The  patient  tolerates  the med-
ication  adequately  without  any report  of significant  adverse
side  effects.
Psychotherapeutic treatment
From  the non-pharmacologic  treatment,  cognitive  behav-
ioral  therapy  (CBT)  proved  to  be the  most  effective;
however,  these interventions  have not  been  proven  efficient
in  the long  run.5,12,13 According  to  Kaplan  and Sadock,  in
both  the individual  and group psychotherapy  fields,  the idea
is  to  help  patients  face  their  somatic  symptoms,  express
subjacent  emotions  and  develop  alternative  strategies  to
express  their  feelings.  Additionally,  some  results  indicate
that  psychodynamic  psychotherapy  is  beneficial  to  psycho-
somatic  patients,  where  the therapeutic  alliance  plays  an
important  role  and  is solidified  through  empathy  with  the
patient’s  suffering.17
Doctors  are not  recommended  to  face  patients  who
somatize  with  comments  like  ‘‘It’s  all  in your head’’.
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Instead,  they  must  recognize  the  reality  of  the physical  ail-
ments,  even  if they  understand  that  their  origin  is  basically
intrapsychic.2,4,5 An  easy  route  of  entry into  the emotional
aspects  of  physical  suffering  is  the examination  of  its  inter-
personal  ramifications  in the  patient’s  life.7,17
We  decided  to  begin  with  individual,  expressive  psycho-
dynamic  psychotherapy,  with  a focus  on  object  relations,
twice  a  week,  in  45--50-min  sessions.  During  the first
6  months  they  included  behavioral  techniques  focused
on  the  urinary  symptom.  These  techniques  consisted  of:
emptying  the  bladder  every  2  h,  going  to  the bathroom
only  to  wash  his  hands  and/or  face and performing  jaw
exercises.
In  parallel  to  the pharmacological  treatment,  the  patient
commits  to psychotherapeutic  treatment,  with  results  which
impacted  his  life  in a  positive  way;  he enrolls  in  univer-
sity,  takes  responsibility  for  his  school  expenses  and his
treatment  and  gradually  becomes  involved  in  social  and
recreational  activities.  The  patient  continues  with  psycho-
dynamic  psychotherapy  to  keep  working  on  his  evasive  and
dependent  personality  traits,  which  contributed  to  the  onset
of  the  physical  symptom  and  the subsequent  personal  and
professional  deterioration.
Therapeutic  plan analysis
The  combination  of treatments  (pharmacological/
psychotherapeutic)  can  be  necessary  in patients  with
severe  SSD  of a  long  evolution  as  in the case  presented,
even  more  when  there  is  a  comorbidity  with  depression
and/or  anxiety.  Consequently,  despite  the fact  that there
is  no  compelling  evidence  for  the effectiveness  of  antide-
pressants  in  SSDs,  the choice  was  based  on  tolerability,
therapeutic  efficiency  in  depression  and  anxiety  and  low
cost,  given  the patient’s  economic  problems.
Despite  the  psychotherapeutic  treatment  of  choice  of
SSDs  being  CBT,  above  the pharmacological  treatment  by
itself  or  any  other  type of psychotherapy,  these  types  of
interventions  have  not  been  proven to  be  effective  in the
long  run,  since most  clinical  trials  only  evaluate  results  in
the  short-term.  In  this  case,  the patient  attends  the  psy-
chiatric  outpatient  clinic  with  the  idea  and  hope  that  his
physical  symptom  may  have  a psychological  cause;  as  well
as  a  great  motivation  to  improve  his  personality  aspects
which  prevented  him from  relating  to  others.  Therefore,
it  is decided  in  conjunction  with  the  patient  to  begin  a
long-term  psychodynamic  psychotherapy  process  comple-
mented  with  behavioral  techniques.  The  success  of  the
treatment  obtained  thus  far  seems  favored  by  a  good ther-
apeutic  alliance,  self-reflective  ability  and  commitment  to
the  treatment.
Conclusions
The  common  characteristic  evolution  of  chronicity,  social
dysfunction,  work  difficulties  and  frequent  use  of  medical
services  lead  to  a level  of dissatisfaction  and frustration  on
the  patient  as  well  as  the doctor,  as  well  as  a high  economic
cost  in  healthcare  services.2,4,5,18
One  of  the most  valuable  contributions  in  the re-
conceptualization  of  the DSM-V  for  somatic  disorders  is
that  it  obliges  all  non-psychiatric  colleagues  in the mental
health  area  to  place  stress,  not  on  the description  of  the
symptom  per  se,  but  in exploring  how  the symptom  affects
the  patient:  (a)  emotionally  (i.e. makes  him depressed,
anguished,  irritated,  etc.);  (b)  cognitively  (i.e. rumination
on  the symptom,  catastrophic  ideas,  etc.);  and  (c)  behav-
iorally  (i.e.  constant  medical  consultations,  stop  working,
etc.).8
Even  though  the chief  complaint  was  pollakiuria,  by
understanding  how  it affected  the patient,  not  only  phys-
ically,  but  also  in  other  aspects  of  his  life  and  his
surroundings,  it  helped  us situate  the  functioning  of  the
symptom  in his  life,  to  have  a  more  realistic  idea  of  the
patient’s  ailment  and  to  have  a more  empathic  treatment
toward  him.  This  more  integral  approach  allowed  the cre-
ation  of  a  treatment  plan  which included  not  only the
symptom,  but  other  aspects  of the  patient’s  life  which  were
subjacent  to  the physical  symptom.
The  DSM-V  modifications  in SSD diagnostic  criteria  lead  all
healthcare  professionals  toward  a  more  integral  evaluation
and  approach,  which  may  help  doctors  to  have  a  more  realis-
tic  comprehension  of  the patient,  thus  avoiding  improper  or
incomplete  diagnosis  and/or  management,  which  only favors
chronicity  and  worsens  prognosis.6,7,9--11,18
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